We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
-22.91%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$131M
AUM Growth
-$149M
(-53%)
Cap. Flow
-$94.6M
Cap. Flow
% of AUM
-72.16%
Top 10 Holdings %
Top 10 Hldgs %
79.41%
Holding
34
New
3
Increased
7
Reduced
6
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$7.68M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$6.68M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$1.98M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$888K |
| 5 |
ACER
Acer Therapeutics Inc
ACER
|
+$777K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$32.9M |
| 2 |
Arrowhead Research
ARWR
|
+$14.9M |
| 3 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$12.1M |
| 4 |
Veracyte
VCYT
|
+$7.69M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$7.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Coherus Oncology
CHRS
$222M
| – | – |
-50,000
| Closed | -$825K |
|
|
27
Coherus Oncology
CHRS
$222M
| – | – |
-353,500
| Closed | -$5.83M |
|
28
Dianthus Therapeutics
DNTH
$5.8B
| – | – |
-10,625
| Closed | -$2.04M |
|
|
29
Madrigal Pharmaceuticals
MDGL
$11.1B
| – | – |
-33,000
| Closed | -$7.07M |
|
30
PUT
Regeneron Pharmaceuticals
REGN
$78.2B
| – | – |
-20,000
| Closed | -$8.08M |
|
|
ALIM
31
DELISTED
Alimera Sciences
ALIM
| – | – |
-17,833
| Closed | -$262K |
|
|
ONCT
32
PUT
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| – | – |
-714
| Closed | -$157K |
|
|
AMAG
33
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
| – | – |
-40,000
| Closed | -$800K |
|
|
ECYT
34
DELISTED
Endocyte, Inc. Common Stock
ECYT
| – | – |
-92,000
| Closed | -$1.63M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q4 2018 Portfolio in Review
As of Q4 2018, Acuta Capital Partners held 34 positions worth $131M, down 53% from $280M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Acuta Capital Partners withdrew a net $94.6M in Q4 2018, closing 13 positions and reducing 6 holdings. Its most notable exit was Arrowhead Research, an estimated $14.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier.
Against the trend, Acuta Capital Partners opened a new position in Sutro Biopharma worth $410K.
- Acuta Capital Partners's largest Q4 2018 buy was Sutro Biopharma: 4,550 shares worth $410K.
- Acuta Capital Partners added most to Iovance Biotherapeutics in Q4 2018, an estimated $7.68M increase.
- Acuta Capital Partners's biggest Q4 2018 reduction was Immunomedics Inc, cutting an estimated $32.9M.
- Acuta Capital Partners fully exited Arrowhead Research in Q4 2018, selling an estimated $14.9M.
- Acuta Capital Partners's ten largest holdings make up 79% of its $131M portfolio in Q4 2018.
- Acuta Capital Partners opened 3 new positions and closed 13 in Q4 2018.
- Acuta Capital Partners's portfolio value fell 53% quarter-over-quarter to $131M.
Based on Acuta Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.